通过四贝纳抑制VMAT2的结构机制
Michael P Dalton1, Mary Hongying Cheng2, Ivet Bahar2
1Department of Structural Biology, University of Pittsburgh, Pittsburgh, United States.
结合甲胺转运体2 (VMAT2) 的第一个结构揭示了这种药物如何抑制VMAT2,为神经递质运输和新疗法设计提供了洞察力.
科学领域:
- 神经科学是一个神经科学.
- 结构生物学 结构生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 膀单胺转运体2 (VMAT2) 对于神经递质包装至关重要,并与神经精神疾病有关.
- 了解VMAT2的机制对于开发帕金森病等疾病的治疗方法以及了解药物作用至关重要.
研究的目的:
- 确定VMAT2.2的高分辨率结构.
- 为了阐明VMAT2抑制的机制由四贝纳 (TBZ).
- 提供有关VMAT2运输和结构动态的见解.
主要方法:
- 低温电子显微镜 (cryo-EM) 在3.1 Å分辨率.
- 对VMAT2-四素复合物的结构分析.
主要成果:
- 该结构显示了tetrabenazine在一个中心部位的结合,诱导了一个封闭的VMAT2形状.
- 确定了细胞质和光门关闭的关键残留物,包括光门关闭的恐水性残留物.
- 突出了三种极性网络,可能涉及质子转导和 conformational 动力学.
结论:
- 该结构为由tetrabenazine的非竞争性VMAT2抑制提供了机制基础.
- 获得了对VMAT2架构,功能和关门机制的洞察力.
- 这些发现有助于合理设计新的VMAT2向治疗方法.
更多相关视频
11:44Cellular Membrane Affinity Chromatography Columns to Identify Specialized Plant Metabolites Interacting with Immobilized Tropomyosin Kinase Receptor B
Published on: January 19, 2022
10:44Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
相关概念视频
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Nondepolarizing (Competitive) Neuromuscular Blockers: Mechanism of Action
Competitive antagonists prevent acetylcholine from binding to its receptor, inhibiting membrane depolarization. Without conformational changes or intrinsic...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
The binding of dantrolene to the RYR1...
Drugs that Destabilize Microtubules
